Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir with Peginterferon alfa-2a and Ribavirin in Prior Non-Responders
NCT00845065Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Primary completion
- Oct 2010
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of boceprevir in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response Rate. Started Feb 2009; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00845065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00845065.